MedTrace Logo

Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist

NCT03133741 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-11-01

No results posted yet for this study

Summary

Delinieation of GIP's effects during an oral glucose tolerance test (OGTT) in humans using GIP receptor antagonisation.

Conditions

  • Glucose Metabolism Disorders

Interventions

OTHER

GIP-A

GIP-A (GIP receptor antagonist)

OTHER

GLP-1 receptor antagonist Exendin[9-39]

Exendin\[9-39\]

OTHER

Placebo

Saline (9mg/mL)

OTHER

GIP-A + Exendin[9-39]

GIP receptor antagonist + GLP-1 receptor antagonist

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Filip K Knop, MD, PhD · UHGentofte, Center for Diabetes Research

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2017-07-01
Completion
2017-07-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03133741 on ClinicalTrials.gov